Enveric Biosciences (NASDAQ:ENVB – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.76) earnings per share (EPS) for the quarter, FiscalAI reports.
Enveric Biosciences Stock Performance
ENVB traded up $0.03 during trading on Friday, reaching $1.53. The stock had a trading volume of 55,644 shares, compared to its average volume of 122,869. The business has a 50-day moving average of $1.44 and a 200-day moving average of $2.12. Enveric Biosciences has a one year low of $1.25 and a one year high of $17.64. The stock has a market cap of $5.65 million, a PE ratio of -0.07 and a beta of 1.13.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on ENVB shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Friday, July 17th. Wall Street Zen cut Enveric Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Enveric Biosciences has a consensus rating of “Sell”.
About Enveric Biosciences
Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.
Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.
Read More
- Five stocks we like better than Enveric Biosciences
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
